Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 13/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5560557 | 0.86 | EPHX1 (0.56) | EPHX1LMNAALDH1A1EPHX2KDM4E | |
| SCHEMBL6872551 | 0.78 | EPHX1 (0.60) | EPHX1LMNAALDH1A1EPHX2KDM4E | |
| SCHEMBL12196071 | 0.78 | EPHX1 (1.00) | EPHX1ALDH1A1EPHX2KDM4ESMN1; SMN2 | |
| SCHEMBL14424447 | 0.75 | EPHX1 (0.66) | EPHX1LMNAALDH1A1EPHX2KDM4E | |
| SCHEMBL8250809 | 0.75 | EPHX1 (0.70) | EPHX1LMNAALDH1A1EPHX2KDM4E | |
| SCHEMBL5554317 | 0.75 | LMNA (0.63) | EPHX1LMNAEPHX2SMN1; SMN2 | |
| SCHEMBL15414684 | 0.74 | EPHX1 (0.39) | EPHX1ALDH1A1EPHX2KDM4E | |
| SCHEMBL9112730 | 0.73 | LMNA (0.61) | EPHX1LMNAALDH1A1EPHX2KDM4E | |
| SCHEMBL9112727 | 0.73 | LMNA (0.61) | EPHX1LMNAALDH1A1EPHX2KDM4E | |
| SCHEMBL2500706 | 0.73 | EPHX1 (0.54) | EPHX1LMNAALDH1A1EPHX2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940785-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SmithKline Beecham Corporation (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2007030761-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | EPHX1 1948/4885LMNA 3671/4885ALDH1A1 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.